Studies such as DAPA-HF and EMPEROR-Reduced have demonstrated that SGLT2 inhibitors not only improve cardiovascular outcomes but also provide renal and metabolic benefits, reinforcing the rationale for comprehensive therapeutic approaches [20,21]. The gene discussed is SLC5A2; the disease is hydrops fetalis.